SSR Health LLC is a sell-side research venture built to provide an essential, yet missing, element of research: the weighting of sub-sectors within the healthcare sector. By simultaneously maintaining both a broad view of our industry, and a fundamentally detailed view of the sub-sectors that make up the industries, we offer guidance on portfolio composition that is both highly impactful, and otherwise unavailable.
Dr. Richard Evans, a 20 year industry veteran, leads SSR Health. As a senior executive in the pharmaceuticals industry, Dr. Evans responsibilities ranged from corporate strategy to the pricing and distribution of the company’s products. His variety of assignments provided a comparable variety of vantage points on the industry. As an analyst with Sanford C. Bernstein, he was ranked #1 by both Bloomberg and Institutional Investor for his U.S. pharmaceuticals coverage – across all industries and coverage he was ranked one of the top 20 analysts worldwide. Dr. Evans is the author of “Health and Capital” published in August of 2009. He is a co-founder of SSR, LLC
Scott Hinds is an experienced economist and a co-architect of the Hidden Pipeline platform. He received his M.S. from the University of North Carolina, where he taught Microeconomics to both graduate and undergraduate students. His degree includes a concentration in Microeconomic Theory and extensive experience in complex econometric techniques. Mr. Hinds’ graduate research focused on information asymmetries and the game theoretical foundations of herd behavior. His work has been published in Nature Reviews Drug Discovery and the Handbook of Public Finance. Mr. Hinds has also worked in investment banking with Lehman Brothers and as a strategic consultant with AVOS Life Sciences. As an equity capital markets financial analyst, Mr. Hinds worked on numerous IPOs, convertible and PIPE offerings for a range of healthcare, biotechnology and industrial companies. More recently he worked as a strategic consultant specializing in large scale quantitative engagements for a number of pharmaceutical clients
Ryan Baum is a longtime analyst at SSR Health. Prior to this, he was a management consultant with IMS Consulting Group, where he advised biopharmaceutical clients on strategic issues pertaining to global pricing and market access, portfolio management, customer engagement and market segmentation, research and development, lifecycle management, value proposition development, mergers and acquisitions due diligence, and response to policy reforms. Mr. Baum earned his BA in Economics, Public Policy Studies, and Philosophy from Duke University